UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 5, 2020
| LEXARIA BIOSCIENCE CORP. |
| (Exact name of registrant as specified in charter) |
| Nevada |
| 000-52138 |
| 20-2000871 |
| (State or other jurisdiction |
| (Commission |
| (IRS Employer |
| of incorporation) |
| File Number) |
| Identification No.) |
100 – 740 McCurdy Road, Kelowna, BC Canada V1X 2P7
(Address of principal executive offices) (Zip Code)
(250) 765-6424
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
| Ticker symbol(s) |
| Name of each exchange on which registered |
| N/A |
| N/A |
| N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On November 5, 2020 Lexaria Bioscience Corp. provided an outline of its planned strategic initiatives for 2021 whereby the focus of its business will be on the out-licensing of its patented DehydraTECH drug delivery technology within four core areas of business:
|
| · | Heart disease including hypertension utilizing CBD; |
|
|
|
|
|
| · | Reduced-risk methods of delivering non-combusted nicotine; |
|
|
|
|
|
| · | Improving antiviral drug delivery for applications that include Covid-19, influenza, herpes, hepatitis and AIDS; and |
|
|
|
|
|
| · | Hemp-based CBD business-to-business (“B2B”) applications for non-pharmaceutical consumer and therapeutic or medicinal products and prospective pharmaceutical indications beyond hypertension. |
| Item 9.01 | Financial Statements And Exhibits. |
| Exhibit No. |
| Description |
|
|
|
|
|
|
| 2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 5, 2020
|
| LEXARIA BIOSCIENCE CORP. |
| |
|
|
|
| |
|
| By: | /s/ Chris Bunka |
|
|
|
| Chris Bunka |
|
|
|
| Chief Executive Officer |
|
| 3 |